➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Boehringer Ingelheim
Medtronic
Dow
Baxter

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021985


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 021985 describes TEKTURNA, which is a drug marketed by Noden Pharma and is included in three NDAs. It is available from two suppliers. There are three patents protecting this drug and two Paragraph IV challenges. Additional details are available on the TEKTURNA profile page.

The generic ingredient in TEKTURNA is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.
Summary for 021985
Tradename:TEKTURNA
Applicant:Noden Pharma
Ingredient:aliskiren hemifumarate
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021985
Mechanism of ActionRenin Inhibitors
Suppliers and Packaging for NDA: 021985
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985 NDA AUTHORIZED GENERIC Prasco Laboratories 66993-141 66993-141-30 30 TABLET, FILM COATED in 1 BOTTLE (66993-141-30)
TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985 NDA AUTHORIZED GENERIC Prasco Laboratories 66993-142 66993-142-30 30 TABLET, FILM COATED in 1 BOTTLE (66993-142-30)
Paragraph IV (Patent) Challenges for 021985
Tradename Dosage Ingredient NDA Submissiondate
TEKTURNA TABLET;ORAL aliskiren hemifumarate 021985 2014-01-27

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 150MG BASE
Approval Date:Mar 5, 2007TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Aug 19, 2026Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 300MG BASE
Approval Date:Mar 5, 2007TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Aug 19, 2026Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Boehringer Ingelheim
Colorcon
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.